Menu
X

China Leading Global Advances in Breast Cancer Immunotherapy

🌟China Leading Global Advances in Breast Cancer Immunotherapy 🌟#ChinaInMedicine #BreastCancer

Breast Cancer

Breast Cancer

Since 2020, breast cancer has surpassed lung cancer, becoming the most common cancer globally with approximately 2.3 million new cases and 680,000 deaths annually. Despite improvements in traditional treatments like surgery, chemotherapy, and radiation, the mortality rate remains high. China’s Chimeric Antigen Receptor (CAR) immunotherapy is making significant strides, spearheading innovation in breast cancer treatment. 🇨🇳💪
 
Recent studies indicate substantial breakthroughs in CAR-T therapy, as well as CAR-NK cells and CAR macrophages for breast cancer treatment. The application of combination therapies further enhances the cytotoxicity of CAR-based cell therapies against breast cancer cells, bringing new hope to patients. 🚀
 
China is at the forefront of global clinical research on CAR, with 16 clinical trials focused on CAR-T or CAR-NK cell therapies currently underway. Particularly noteworthy is the research at the People’s Liberation Army General Hospital, where CAR-T cells targeting CD133 are employed to treat refractory advanced malignant tumors, including breast cancer. This approach has demonstrated excellent anti-tumor activity and manageable safety in patients previously treated for advanced hepatocellular carcinoma and cholangiocarcinoma. 🏥✨
 
On another front, the clinical study at Sun Yat-sen Memorial Hospital, Zhongshan University, is equally intriguing. They are exploring PD-1 knockout CAR-T cells targeting MUC1 for treating late-stage breast cancer patients. This trial is a dose-escalation exploratory study, and researchers anticipate its results to pave the way for future treatments. 🧪🔍
 
China is not only a trailblazer in breast cancer immunotherapy research but also a miracle creator, bringing new hope to cancer patients worldwide. Let’s witness China’s outstanding achievements in the medical field and acknowledge its contribution to global health! 💊🌏
 
#ImmunotherapyAdvancements #BreastCancerResearch

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.